Condition: Multiple Myeloma · B-cell Lymphoma · Hematological Malignancy · Sponsor: The Third Affiliated Hospital of Southern Medical University
This is a single center, open-label, dose-escalation/expansion clinical study to evaluate the safety and effectiveness of Fourth-Generation CAR-T, and determine the recommended dose of the CAR T-cells for patients with Multiple Myeloma，B-cell lymphoma and other hematologic malignancies.
This description comes directly from the study's public registry record.
Yan Yi, MD. · +86 13617493781 · yiyan@smu.edu.cn
Always discuss trial participation with your own doctor first.
| The Third Affiliated Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06758713